1	Direct 	O
2	current 	O
3	polarography 	O
4	and 	O
5	differential 	O
6	pulse 	O
7	polarographic 	O
8	methods 	O
9	have 	O
10	been 	O
11	developed 	O
12	for 	O
13	the 	O
14	qualitative 	O
15	as 	O
16	well 	O
17	as 	O
18	quantitative 	O
19	analysis 	O
20	of 	O
21	vitamin 	O
22	B1 	O
23	, 	O
24	B2 	O
25	and 	O
26	B6 	O
27	. 	O

1	Fluorimetric 	O
2	determination 	O
3	of 	O
4	methylmercury 	O
5	as 	O
6	an 	O
7	ion 	O
8	- 	O
9	association 	O
10	complex 	O
11	with 	O
12	rhodamine 	O
13	B 	O
14	in 	O
15	the 	O
16	presence 	O
17	of 	O
18	iodide 	O
19	. 	O

1	The 	O
2	corresponding 	O
3	genotype 	O
4	was 	O
5	determined 	O
6	with 	O
7	a 	O
8	restriction 	O
9	enzyme 	O
10	- 	O
11	based 	O
12	assay 	O
13	. 	O

1	Patients 	O
2	were 	O
3	divided 	O
4	into 	O
5	two 	O
6	group 	O
7	; 	O
8	Control 	O
9	group 	O
10	A 	O
11	in 	O
12	which 	O
13	a 	O
14	hot 	O
15	- 	O
16	water 	O
17	circulating 	O
18	system 	O
19	was 	O
20	used 	O
21	and 	O
22	group 	O
23	B 	O
24	in 	O
25	which 	O
26	a 	O
27	transtracheal 	O
28	heating 	O
29	and 	O
30	humidification 	O
31	system 	O
32	by 	O
33	ANAMED 	O
34	HUMITUBE 	O
35	was 	O
36	used 	O
37	, 	O
38	during 	O
39	gastric 	O
40	cancer 	O
41	operation 	O
42	. 	O

1	Mental 	O
2	rotation 	O
3	of 	O
4	paired 	O
5	figures 	O
6	engendered 	O
7	activation 	O
8	in 	O
9	the 	O
10	left 	O
11	superior 	O
12	parietal 	O
13	lobule 	O
14	and 	O
15	the 	O
16	right 	O
17	frontal 	O
18	medial 	O
19	gyrus 	O
20	. 	O

1	Here 	O
2	we 	O
3	demonstrate 	O
4	that 	O
5	the 	O
6	Ras 	B
7	- 	O
8	activated 	O
9	Raf 	B
10	- 	O
11	MEK 	B
12	- 	O
13	extracellular 	B
14	signal 	I
15	- 	I
16	regulated 	I
17	kinase 	I
18	( 	O
19	ERK 	B
20	) 	O
21	signaling 	O
22	pathway 	O
23	can 	O
24	specifically 	O
25	control 	O
26	the 	O
27	expression 	O
28	of 	O
29	individual 	O
30	integrin 	B
31	subunits 	I
32	in 	O
33	a 	O
34	variety 	O
35	of 	O
36	human 	O
37	and 	O
38	mouse 	O
39	cell 	O
40	lines 	O
41	. 	O

1	These 	O
2	TxRE 	B
3	contain 	O
4	cyclic 	O
5	AMP 	O
6	- 	O
7	responsive 	O
8	elements 	O
9	( 	O
10	CRE 	O
11	), 	O
12	but 	O
13	, 	O
14	remarkably 	O
15	, 	O
16	the 	O
17	" 	O
18	TGACGTCA 	O
19	" 	O
20	consensus 	O
21	is 	O
22	never 	O
23	strictly 	O
24	conserved 	O
25	in 	O
26	any 	O
27	viral 	O
28	strain 	O
29	( 	O
30	e 	O
31	. 	O
32	g 	O
33	., 	O
34	AGACGTCA 	O
35	, 	O
36	TGACGGCA 	O
37	, 	O
38	TGACCTCA 	O
39	). 	O

1	The 	O
2	hatcher 	O
3	incubators 	O
4	of 	O
5	both 	O
6	companies 	O
7	were 	O
8	also 	O
9	persistently 	O
10	contaminated 	O
11	with 	O
12	Salmonella 	O
13	livingstone 	O
14	and 	O
15	Salmonella 	O
16	thomasville 	O
17	in 	O
18	company 	O
19	A 	O
20	and 	O
21	with 	O
22	Salmonella 	O
23	senftenberg 	O
24	in 	O
25	company 	O
26	B 	O
27	. 	O

1	Binding 	O
2	of 	O
3	cell 	O
4	type 	O
5	- 	O
6	specific 	O
7	nuclear 	O
8	proteins 	O
9	to 	O
10	the 	O
11	5 	O
12	'- 	O
13	flanking 	O
14	region 	O
15	of 	O
16	maize 	B
17	C4 	I
18	phosphoenolpyruvate 	I
19	carboxylase 	I
20	gene 	I
21	confers 	O
22	its 	O
23	differential 	O
24	transcription 	O
25	in 	O
26	mesophyll 	O
27	cells 	O
28	. 	O

1	Susceptibility 	O
2	to 	O
3	ischemia 	O
4	- 	O
5	induced 	O
6	arrhythmias 	O
7	was 	O
8	lower 	O
9	in 	O
10	1 	O
11	- 	O
12	week 	O
13	diabetics 	O
14	: 	O
15	only 	O
16	42 	O
17	% 	O
18	of 	O
19	diabetic 	O
20	hearts 	O
21	exhibited 	O
22	ventricular 	O
23	tachycardia 	O
24	( 	O
25	VT 	O
26	) 	O
27	and 	O
28	16 	O
29	% 	O
30	had 	O
31	short 	O
32	episodes 	O
33	of 	O
34	ventricular 	O
35	fibrillation 	O
36	( 	O
37	VF 	O
38	) 	O
39	as 	O
40	compared 	O
41	to 	O
42	VT 	O
43	100 	O
44	% 	O
45	and 	O
46	VF 	O
47	70 	O
48	% 	O
49	( 	O
50	including 	O
51	sustained 	O
52	VF 	O
53	36 	O
54	%) 	O
55	in 	O
56	the 	O
57	non 	O
58	- 	O
59	diabetics 	O
60	( 	O
61	P 	O
62	< 	O
63	0 	O
64	. 	O
65	05 	O
66	). 	O

1	CONCLUSIONS 	O
2	: 	O
3	The 	O
4	methodology 	O
5	of 	O
6	LHR 	O
7	measurement 	O
8	significantly 	O
9	influences 	O
10	the 	O
11	clinical 	O
12	contribution 	O
13	of 	O
14	Tl 	O
15	- 	O
16	201 	O
17	lung 	O
18	uptake 	O
19	evaluation 	O
20	. 	O

1	The 	O
2	authors 	O
3	made 	O
4	an 	O
5	analysis 	O
6	of 	O
7	social 	O
8	- 	O
9	economical 	O
10	conditions 	O
11	limiting 	O
12	the 	O
13	possibilities 	O
14	of 	O
15	rendering 	O
16	cardiosurgical 	O
17	care 	O
18	to 	O
19	children 	O
20	. 	O

1	METHODS 	O
2	: 	O
3	Experiments 	O
4	testing 	O
5	the 	O
6	new 	O
7	catheter 	O
8	and 	O
9	comparing 	O
10	it 	O
11	to 	O
12	the 	O
13	existing 	O
14	catheter 	O
15	included 	O
16	: 	O
17	( 	O
18	1 	O
19	) 	O
20	measurement 	O
21	of 	O
22	the 	O
23	laser 	O
24	output 	O
25	beam 	O
26	sizes 	O
27	and 	O
28	divergences 	O
29	; 	O
30	( 	O
31	2 	O
32	) 	O
33	evaluation 	O
34	of 	O
35	particulate 	O
36	matter 	O
37	generation 	O
38	during 	O
39	ablation 	O
40	of 	O
41	atherosclerotic 	O
42	tissue 	O
43	; 	O
44	( 	O
45	3 	O
46	) 	O
47	measurement 	O
48	of 	O
49	ablation 	O
50	hole 	O
51	sizes 	O
52	and 	O
53	tissue 	O
54	penetration 	O
55	rates 	O
56	; 	O
57	( 	O
58	4 	O
59	) 	O
60	histopathologic 	O
61	examination 	O
62	of 	O
63	laser 	O
64	- 	O
65	induced 	O
66	in 	O
67	vivo 	O
68	vessel 	O
69	wall 	O
70	injury 	O
71	. 	O

1	The 	O
2	reproductive 	O
3	effects 	O
4	of 	O
5	the 	O
6	administration 	O
7	of 	O
8	4 	O
9	- 	O
10	chloro 	O
11	- 	O
12	2 	O
13	- 	O
14	methylphenoxyacetic 	O
15	acid 	O
16	( 	O
17	MCPA 	O
18	) 	O
19	to 	O
20	rats 	O
21	were 	O
22	evaluated 	O
23	through 	O
24	two 	O
25	generations 	O
26	, 	O
27	from 	O
28	prior 	O
29	to 	O
30	mating 	O
31	, 	O
32	throughout 	O
33	mating 	O
34	, 	O
35	to 	O
36	gestation 	O
37	and 	O
38	lactation 	O
39	. 	O

1	Here 	O
2	we 	O
3	suggest 	O
4	that 	O
5	uvrA 	B
6	and 	O
7	the 	O
8	nucleotide 	O
9	excision 	O
10	repair 	O
11	pathway 	O
12	are 	O
13	involved 	O
14	in 	O
15	the 	O
16	repair 	O
17	of 	O
18	acid 	O
19	- 	O
20	induced 	O
21	DNA 	O
22	damage 	O
23	and 	O
24	are 	O
25	associated 	O
26	with 	O
27	successful 	O
28	adaptation 	O
29	of 	O
30	S 	O
31	. 	O
32	mutans 	O
33	to 	O
34	low 	O
35	pH 	O
36	. 	O

1	The 	O
2	improved 	O
3	CSF 	O
4	outflow 	O
5	conductance 	O
6	may 	O
7	increase 	O
8	the 	O
9	intracranial 	O
10	compliance 	O
11	and 	O
12	thereby 	O
13	dampen 	O
14	a 	O
15	pathological 	O
16	ICP 	O
17	waveform 	O
18	. 	O

1	These 	O
2	studies 	O
3	demonstrate 	O
4	that 	O
5	site 	O
6	- 	O
7	specific 	O
8	recognition 	O
9	of 	O
10	the 	O
11	bxd 	B
12	PRE 	I
13	by 	O
14	d 	O
15	( 	O
16	GA 	O
17	)( 	O
18	n 	O
19	) 	O
20	repeat 	O
21	binding 	O
22	activities 	O
23	mediates 	O
24	PcG 	B
25	- 	O
26	dependent 	O
27	silencing 	O
28	. 	O

1	The 	O
2	gonadotrope 	O
3	- 	O
4	specific 	O
5	and 	O
6	regulated 	O
7	expression 	O
8	of 	O
9	the 	O
10	GnRH 	B
11	receptor 	I
12	( 	O
13	GnRH 	B
14	- 	I
15	R 	I
16	) 	O
17	gene 	O
18	is 	O
19	dependent 	O
20	on 	O
21	multiple 	O
22	transcription 	O
23	factors 	O
24	that 	O
25	interact 	O
26	with 	O
27	the 	O
28	noncanonical 	B
29	GnRH 	I
30	- 	I
31	R 	I
32	activating 	I
33	sequence 	I
34	( 	O
35	GRAS 	B
36	), 	O
37	the 	O
38	activator 	B
39	protein 	I
40	- 	I
41	1 	I
42	( 	O
43	AP 	B
44	- 	I
45	1 	I
46	) 	O
47	element 	O
48	, 	O
49	and 	O
50	the 	O
51	steroidogenic 	B
52	factor 	I
53	- 	I
54	1 	I
55	( 	O
56	SF 	B
57	- 	I
58	1 	I
59	) 	O
60	binding 	O
61	site 	O
62	. 	O

1	Before 	O
2	PO3 	O
3	administration 	O
4	, 	O
5	more 	O
6	than 	O
7	half 	O
8	( 	O
9	57 	O
10	. 	O
11	4 	O
12	%) 	O
13	of 	O
14	the 	O
15	patients 	O
16	received 	O
17	only 	O
18	1 	O
19	or 	O
20	2 	O
21	antituberculous 	O
22	drugs 	O
23	( 	O
24	ethambutole 	O
25	and 	O
26	ethionamide 	O
27	or 	O
28	ethambutole 	O
29	and 	O
30	oprofloxacin 	O
31	). 	O

1	Using 	O
2	the 	O
3	presented 	O
4	categorical 	O
5	structure 	O
6	as 	O
7	domain 	O
8	model 	O
9	a 	O
10	prototype 	O
11	DSS 	O
12	for 	O
13	dipslide 	O
14	urine 	O
15	cultures 	O
16	has 	O
17	been 	O
18	developed 	O
19	. 	O

1	Conclusion 	O
2	: 	O
3	The 	O
4	Lp 	B
5	( 	I
6	a 	I
7	) 	I
8	levels 	O
9	in 	O
10	these 	O
11	children 	O
12	were 	O
13	the 	O
14	lower 	O
15	ever 	O
16	reported 	O
17	. 	O

1	Foxp1 	B
2	and 	O
3	Foxp2 	B
4	are 	O
5	expressed 	O
6	at 	O
7	high 	O
8	levels 	O
9	in 	O
10	the 	O
11	lung 	O
12	as 	O
13	early 	O
14	as 	O
15	E12 	O
16	. 	O
17	5 	O
18	of 	O
19	mouse 	O
20	development 	O
21	with 	O
22	Foxp2 	B
23	expression 	O
24	restricted 	O
25	to 	O
26	the 	O
27	airway 	O
28	epithelium 	O
29	. 	O

1	Audiological 	O
2	findings 	O
3	in 	O
4	pregnancy 	O
5	. 	O

1	Children 	O
2	who 	O
3	developed 	O
4	lower 	O
5	respiratory 	O
6	tract 	O
7	infections 	O
8	or 	O
9	PCP 	O
10	had 	O
11	increased 	O
12	rates 	O
13	of 	O
14	decline 	O
15	of 	O
16	CD4 	B
17	cell 	O
18	counts 	O
19	during 	O
20	the 	O
21	first 	O
22	6 	O
23	months 	O
24	of 	O
25	life 	O
26	. 	O

1	A 	O
2	randomized 	O
3	mix 	O
4	of 	O
5	180 	O
6	sections 	O
7	( 	O
8	10 	O
9	samples 	O
10	x 	O
11	3 	O
12	tissues 	O
13	x 	O
14	3 	O
15	stains 	O
16	x 	O
17	2 	O
18	) 	O
19	gave 	O
20	90 	O
21	matched 	O
22	pairs 	O
23	. 	O

1	Sural 	O
2	nerve 	O
3	biopsy 	O
4	showed 	O
5	mild 	O
6	thickening 	O
7	of 	O
8	the 	O
9	perineurium 	O
10	, 	O
11	vascular 	O
12	alterations 	O
13	with 	O
14	inflammatory 	O
15	cell 	O
16	infiltration 	O
17	in 	O
18	the 	O
19	perineurium 	O
20	, 	O
21	and 	O
22	remarkable 	O
23	loss 	O
24	of 	O
25	large 	O
26	and 	O
27	small 	O
28	myelinated 	O
29	fibers 	O
30	. 	O

1	OBJECTIVES 	O
2	: 	O
3	The 	O
4	objective 	O
5	of 	O
6	this 	O
7	review 	O
8	was 	O
9	to 	O
10	assess 	O
11	the 	O
12	effects 	O
13	of 	O
14	prophylactic 	O
15	prostaglandin 	O
16	use 	O
17	in 	O
18	the 	O
19	third 	O
20	stage 	O
21	of 	O
22	labour 	O
23	. 	O

1	Testing 	O
2	was 	O
3	associated 	O
4	with 	O
5	a 	O
6	history 	O
7	of 	O
8	nonsexual 	O
9	risk 	O
10	behavior 	O
11	, 	O
12	increased 	O
13	knowledge 	O
14	of 	O
15	the 	O
16	hepatitis 	O
17	C 	O
18	virus 	O
19	, 	O
20	and 	O
21	healthcare 	O
22	provider 	O
23	communication 	O
24	. 	O

1	Cytomegalovirus 	O
2	, 	O
3	Chlamydia 	O
4	pneumoniae 	O
5	, 	O
6	and 	O
7	Helicobacter 	O
8	pylori 	O
9	IgG 	B
10	antibodies 	I
11	and 	O
12	restenosis 	O
13	after 	O
14	stent 	O
15	implantation 	O
16	: 	O
17	an 	O
18	angiographic 	O
19	and 	O
20	intravascular 	O
21	ultrasound 	O
22	study 	O
23	. 	O

1	A 	O
2	5 	O
3	- 	O
4	month 	O
5	- 	O
6	old 	O
7	infant 	O
8	with 	O
9	persistent 	O
10	congenital 	O
11	stridor 	O
12	and 	O
13	acute 	O
14	respiratory 	O
15	distress 	O
16	is 	O
17	presented 	O
18	. 	O

1	OBJECTIVE 	O
2	: 	O
3	To 	O
4	determine 	O
5	whether 	O
6	RSTD 	O
7	predicts 	O
8	coronary 	O
9	anatomy 	O
10	during 	O
11	acute 	O
12	coronary 	O
13	occlusion 	O
14	. 	O

1	Even 	O
2	if 	O
3	the 	O
4	electrocardiographic 	O
5	signs 	O
6	are 	O
7	subdued 	O
8	, 	O
9	the 	O
10	underlying 	O
11	blockade 	O
12	of 	O
13	I 	O
14	( 	O
15	Kr 	O
16	) 	O
17	current 	O
18	may 	O
19	precipitate 	O
20	the 	O
21	occurrence 	O
22	of 	O
23	arrhythmia 	O
24	. 	O

1	Acetoin 	O
2	can 	O
3	be 	O
4	reused 	O
5	by 	O
6	the 	O
7	bacteria 	O
8	during 	O
9	stationary 	O
10	phase 	O
11	when 	O
12	other 	O
13	carbon 	O
14	sources 	O
15	have 	O
16	been 	O
17	depleted 	O
18	. 	O

1	Analysis 	O
2	of 	O
3	the 	O
4	promoter 	O
5	sequence 	O
6	revealed 	O
7	the 	O
8	presence 	O
9	of 	O
10	a 	O
11	major 	O
12	transcriptional 	O
13	start 	O
14	site 	O
15	, 	O
16	a 	O
17	canonical 	O
18	TATA 	O
19	box 	O
20	and 	O
21	putative 	O
22	cis 	O
23	regulatory 	O
24	elements 	O
25	for 	O
26	pituitary 	O
27	specific 	O
28	expression 	O
29	as 	O
30	well 	O
31	as 	O
32	an 	O
33	E 	O
34	- 	O
35	responsive 	O
36	element 	O
37	. 	O

1	IL 	B
2	- 	I
3	1beta 	I
4	was 	O
5	significantly 	O
6	higher 	O
7	in 	O
8	endometrioma 	O
9	than 	O
10	in 	O
11	lesions 	O
12	of 	O
13	other 	O
14	localizations 	O
15	. 	O

1	An 	O
2	economic 	O
3	analysis 	O
4	using 	O
5	West 	O
6	of 	O
7	Scotland 	O
8	Coronary 	O
9	Prevention 	O
10	Study 	O
11	( 	O
12	WOSCOPS 	O
13	) 	O
14	findings 	O
15	indicates 	O
16	that 	O
17	statin 	B
18	treatment 	O
19	would 	O
20	have 	O
21	prevented 	O
22	318 	O
23	events 	O
24	per 	O
25	10 	O
26	, 	O
27	000 	O
28	patients 	O
29	in 	O
30	a 	O
31	population 	O
32	similar 	O
33	to 	O
34	that 	O
35	in 	O
36	WOSCOPS 	O
37	( 	O
38	average 	O
39	1 	O
40	. 	O
41	5 	O
42	% 	O
43	annual 	O
44	risk 	O
45	of 	O
46	a 	O
47	cardiovascular 	O
48	event 	O
49	) 	O
50	at 	O
51	a 	O
52	discounted 	O
53	cost 	O
54	per 	O
55	life 	O
56	- 	O
57	year 	O
58	gained 	O
59	of 	O
60	20 	O
61	, 	O
62	375 	O
63	pounds 	O
64	($ 	O
65	31 	O
66	, 	O
67	818 	O
68	). 	O

1	Hydrogels 	O
2	for 	O
3	tissue 	O
4	engineering 	O
5	. 	O

1	No 	O
2	mutation 	O
3	of 	O
4	the 	O
5	NRL 	B
6	gene 	I
7	was 	O
8	found 	O
9	in 	O
10	any 	O
11	of 	O
12	the 	O
13	two 	O
14	families 	O
15	. 	O

1	However 	O
2	, 	O
3	most 	O
4	produced 	O
5	significant 	O
6	alteration 	O
7	of 	O
8	small 	O
9	intestinal 	O
10	permeability 	O
11	. 	O

1	Our 	O
2	results 	O
3	show 	O
4	that 	O
5	CVN 	B
6	specifically 	O
7	recognizes 	O
8	with 	O
9	nanomolar 	O
10	affinity 	O
11	Man 	O
12	( 	O
13	9 	O
14	) 	O
15	GlcNAc 	O
16	( 	O
17	2 	O
18	) 	O
19	and 	O
20	the 	O
21	D1D3 	O
22	isomer 	O
23	of 	O
24	Man 	O
25	( 	O
26	8 	O
27	) 	O
28	GlcNAc 	O
29	( 	O
30	2 	O
31	). 	O

1	Saccharomyces 	O
2	cerevisiae 	O
3	activates 	O
4	a 	O
5	regulatory 	O
6	network 	O
7	called 	O
8	" 	O
9	general 	O
10	control 	O
11	" 	O
12	that 	O
13	provides 	O
14	the 	O
15	cell 	O
16	with 	O
17	sufficient 	O
18	amounts 	O
19	of 	O
20	protein 	O
21	precursors 	O
22	during 	O
23	amino 	O
24	acid 	O
25	starvation 	O
26	. 	O

1	In 	O
2	Saccharomyces 	O
3	cerevisiae 	O
4	, 	O
5	entry 	O
6	into 	O
7	mitosis 	O
8	requires 	O
9	activation 	O
10	of 	O
11	the 	O
12	cyclin 	B
13	- 	I
14	dependent 	I
15	kinase 	I
16	Cdc28 	I
17	in 	O
18	its 	O
19	cyclin 	B
20	B 	I
21	( 	O
22	Clb 	B
23	)- 	O
24	associated 	O
25	form 	O
26	. 	O

1	Data 	O
2	from 	O
3	in 	O
4	vitro 	O
5	splicing 	O
6	assays 	O
7	, 	O
8	UV 	O
9	crosslinking 	O
10	and 	O
11	RNA 	O
12	- 	O
13	binding 	O
14	competition 	O
15	experiments 	O
16	indicates 	O
17	a 	O
18	strong 	O
19	correlation 	O
20	between 	O
21	the 	O
22	binding 	O
23	affinities 	O
24	of 	O
25	PSI 	B
26	for 	O
27	the 	O
28	SELEX 	O
29	sequences 	O
30	and 	O
31	their 	O
32	ability 	O
33	to 	O
34	modulate 	O
35	splicing 	O
36	of 	O
37	P 	B
38	element 	I
39	IVS3 	I
40	in 	O
41	vitro 	O
42	. 	O

1	The 	O
2	sensitivity 	O
3	of 	O
4	human 	O
5	neuroblastoma 	O
6	cells 	O
7	SK 	O
8	- 	O
9	N 	O
10	- 	O
11	SH 	O
12	to 	O
13	undergo 	O
14	apoptosis 	O
15	induced 	O
16	by 	O
17	thapsigargin 	O
18	was 	O
19	examined 	O
20	. 	O

1	A 	O
2	., 	O
3	Slatkin 	O
4	, 	O
5	D 	O
6	. 	O

1	Multiparous 	O
2	women 	O
3	presented 	O
4	higher 	O
5	BMI 	O
6	( 	O
7	P 	O
8	= 	O
9	0 	O
10	. 	O
11	01 	O
12	) 	O
13	and 	O
14	PBF 	O
15	( 	O
16	P 	O
17	= 	O
18	0 	O
19	. 	O
20	03 	O
21	) 	O
22	compared 	O
23	with 	O
24	primi 	O
25	- 	O
26	and 	O
27	nulliparous 	O
28	groups 	O
29	. 	O

1	CONCLUSIONS 	O
2	AND 	O
3	CLINICAL 	O
4	RELEVANCE 	O
5	: 	O
6	Increased 	O
7	cortical 	O
8	thickness 	O
9	and 	O
10	geometric 	O
11	properties 	O
12	of 	O
13	left 	O
14	MCB 	O
15	- 	O
16	IV 	O
17	and 	O
18	- 	O
19	V 	O
20	of 	O
21	Greyhounds 	O
22	, 	O
23	together 	O
24	with 	O
25	altered 	O
26	turnover 	O
27	and 	O
28	orientation 	O
29	of 	O
30	osteons 	O
31	in 	O
32	the 	O
33	dorsal 	O
34	quadrants 	O
35	of 	O
36	left 	O
37	MCB 	O
38	, 	O
39	are 	O
40	site 	O
41	- 	O
42	specific 	O
43	adaptive 	O
44	responses 	O
45	associated 	O
46	with 	O
47	asymmetric 	O
48	cyclic 	O
49	loading 	O
50	as 	O
51	a 	O
52	result 	O
53	of 	O
54	racing 	O
55	on 	O
56	circular 	O
57	tracks 	O
58	. 	O

1	To 	O
2	examine 	O
3	transcriptional 	O
4	regulation 	O
5	of 	O
6	the 	O
7	rat 	B
8	eIF4E 	I
9	gene 	I
10	, 	O
11	2 	O
12	. 	O
13	1 	O
14	kB 	O
15	of 	O
16	the 	O
17	rat 	B
18	eIF4E 	I
19	promoter 	I
20	region 	I
21	was 	O
22	cloned 	O
23	and 	O
24	the 	O
25	contribution 	O
26	of 	O
27	specific 	O
28	elements 	O
29	in 	O
30	regulating 	O
31	transcription 	O
32	was 	O
33	determined 	O
34	in 	O
35	primary 	O
36	cultures 	O
37	of 	O
38	rat 	O
39	cardiocytes 	O
40	and 	O
41	in 	O
42	a 	O
43	murine 	O
44	C 	O
45	( 	O
46	2 	O
47	) 	O
48	C 	O
49	( 	O
50	12 	O
51	) 	O
52	myoblast 	O
53	cell 	O
54	line 	O
55	. 	O

1	The 	O
2	prevalence 	O
3	of 	O
4	tobacco 	O
5	dependence 	O
6	diagnosed 	O
7	according 	O
8	to 	O
9	the 	O
10	ICD 	O
11	- 	O
12	10 	O
13	criteria 	O
14	was 	O
15	higher 	O
16	in 	O
17	alcohol 	O
18	- 	O
19	dependent 	O
20	individuals 	O
21	( 	O
22	58 	O
23	. 	O
24	1 	O
25	%) 	O
26	than 	O
27	in 	O
28	nondrinkers 	O
29	or 	O
30	social 	O
31	drinkers 	O
32	( 	O
33	12 	O
34	. 	O
35	8 	O
36	%). 	O

1	Management 	O
2	of 	O
3	postvitrectomy 	O
4	diabetic 	O
5	vitreous 	O
6	hemorrhage 	O
7	with 	O
8	tissue 	B
9	plasminogen 	I
10	activator 	I
11	( 	O
12	t 	B
13	- 	I
14	PA 	I
15	) 	O
16	and 	O
17	volume 	O
18	homeostatic 	O
19	fluid 	O
20	- 	O
21	fluid 	O
22	exchanger 	O
23	. 	O

1	Transactivation 	O
2	of 	O
3	oIFNtau 	B
4	enhancer 	O
5	- 	O
6	reporter 	O
7	constructs 	O
8	was 	O
9	primarily 	O
10	regulated 	O
11	by 	O
12	three 	O
13	regions 	O
14	containing 	O
15	AP 	B
16	- 	I
17	1 	I
18	site 	I
19	, 	O
20	GATA 	B
21	like 	I
22	sequence 	I
23	and 	O
24	site 	O
25	( 	O
26	s 	O
27	) 	O
28	unidentified 	O
29	. 	O

1	SELECTION 	O
2	CRITERIA 	O
3	: 	O
4	Randomised 	O
5	controlled 	O
6	trials 	O
7	of 	O
8	cabergoline 	O
9	versus 	O
10	placebo 	O
11	in 	O
12	patients 	O
13	with 	O
14	a 	O
15	clinical 	O
16	diagnosis 	O
17	of 	O
18	idiopathic 	O
19	Parkinson 	O
20	' 	O
21	s 	O
22	disease 	O
23	and 	O
24	long 	O
25	- 	O
26	term 	O
27	complications 	O
28	of 	O
29	levodopa 	O
30	therapy 	O
31	. 	O

1	0 	O
2	%) 	O
3	and 	O
4	IL 	B
5	- 	I
6	12 	I
7	( 	O
8	42 	O
9	. 	O
10	6 	O
11	% 	O
12	vs 	O
13	. 	O

1	Copyright 	O
2	2000 	O
3	John 	O
4	Wiley 	O
5	& 	O
6	Sons 	O
7	, 	O
8	Ltd 	O
9	. 	O

1	Here 	O
2	we 	O
3	demonstrate 	O
4	that 	O
5	native 	B
6	MRCK 	I
7	exists 	O
8	in 	O
9	high 	O
10	- 	O
11	molecular 	O
12	- 	O
13	weight 	O
14	complexes 	O
15	. 	O

1	METHODS 	O
2	: 	O
3	This 	O
4	retrospective 	O
5	review 	O
6	comprised 	O
7	2711 	O
8	eyes 	O
9	that 	O
10	had 	O
11	LASIK 	O
12	between 	O
13	September 	O
14	1996 	O
15	and 	O
16	September 	O
17	1999 	O
18	. 	O

1	Sixty 	O
2	- 	O
3	one 	O
4	cases 	O
5	of 	O
6	cholera 	O
7	, 	O
8	all 	O
9	caused 	O
10	by 	O
11	V 	O
12	. 	O
13	cholerae 	O
14	O1 	O
15	, 	O
16	were 	O
17	reported 	O
18	. 	O

1	This 	O
2	could 	O
3	lead 	O
4	to 	O
5	subsequent 	O
6	outbreaks 	O
7	if 	O
8	Babesia 	O
9	carrier 	O
10	animals 	O
11	were 	O
12	to 	O
13	be 	O
14	introduced 	O
15	into 	O
16	the 	O
17	herd 	O
18	. 	O

1	Instead 	O
2	, 	O
3	TRPS1 	B
4	potently 	O
5	and 	O
6	specifically 	O
7	represses 	O
8	transcriptional 	O
9	activation 	O
10	mediated 	O
11	by 	O
12	other 	O
13	GATA 	B
14	factors 	I
15	. 	O

1	Eliminating 	O
2	any 	O
3	subset 	O
4	of 	O
5	ASCUS 	O
6	reduces 	O
7	the 	O
8	ASCUS 	O
9	/ 	O
10	SIL 	O
11	ratio 	O
12	but 	O
13	also 	O
14	significantly 	O
15	diminishes 	O
16	the 	O
17	sensitivity 	O
18	of 	O
19	the 	O
20	Papanicolaou 	O
21	test 	O
22	. 	O

1	In 	O
2	order 	O
3	to 	O
4	overcome 	O
5	the 	O
6	false 	O
7	positive 	O
8	readings 	O
9	that 	O
10	are 	O
11	possible 	O
12	in 	O
13	sphincter 	O
14	manometry 	O
15	, 	O
16	we 	O
17	proposed 	O
18	to 	O
19	use 	O
20	secretin 	B
21	stimulated 	O
22	endoscopic 	O
23	ultrasound 	O
24	( 	O
25	SSEUS 	O
26	) 	O
27	to 	O
28	measure 	O
29	pancreatic 	O
30	ductal 	O
31	response 	O
32	as 	O
33	an 	O
34	adjunctive 	O
35	method 	O
36	to 	O
37	aid 	O
38	and 	O
39	supplement 	O
40	the 	O
41	diagnosis 	O
42	. 	O

1	Endovascular 	O
2	aneurysm 	O
3	repair 	O
4	with 	O
5	the 	O
6	AneuRx 	O
7	stent 	O
8	- 	O
9	graft 	O
10	is 	O
11	safe 	O
12	, 	O
13	but 	O
14	is 	O
15	it 	O
16	effective 	O
17	? 	O

1	The 	O
2	difference 	O
3	of 	O
4	hardness 	O
5	over 	O
6	time 	O
7	of 	O
8	composite 	O
9	specimens 	O
10	was 	O
11	measured 	O
12	using 	O
13	Knoop 	O
14	hardness 	O
15	measurements 	O
16	taken 	O
17	at 	O
18	the 	O
19	top 	O
20	and 	O
21	bottom 	O
22	surfaces 	O
23	of 	O
24	resin 	O
25	specimens 	O
26	made 	O
27	in 	O
28	a 	O
29	Teflon 	O
30	mold 	O
31	the 	O
32	same 	O
33	dimensions 	O
34	as 	O
35	the 	O
36	cavity 	O
37	prepared 	O
38	in 	O
39	dentin 	O
40	. 	O

1	Implications 	O
2	in 	O
3	biomonitoring 	O
4	of 	O
5	the 	O
6	observed 	O
7	accumulation 	O
8	patterns 	O
9	, 	O
10	especially 	O
11	in 	O
12	the 	O
13	different 	O
14	tissues 	O
15	of 	O
16	Posidonia 	O
17	oceanica 	O
18	, 	O
19	are 	O
20	discussed 	O
21	. 	O

1	Based 	O
2	on 	O
3	mutational 	O
4	data 	O
5	and 	O
6	possible 	O
7	mRNA 	O
8	structure 	O
9	, 	O
10	we 	O
11	hypothesized 	O
12	about 	O
13	the 	O
14	effect 	O
15	of 	O
16	mRNA 	O
17	structure 	O
18	on 	O
19	translation 	O
20	of 	O
21	the 	O
22	two 	O
23	major 	O
24	C 	B
25	/ 	I
26	EBPepsilon 	I
27	isoforms 	I
28	: 	O
29	p32 	B
30	and 	O
31	p30 	B
32	. 	O

1	Retinoids 	O
2	participate 	O
3	in 	O
4	the 	O
5	onset 	O
6	of 	O
7	differentiation 	O
8	, 	O
9	apoptosis 	O
10	and 	O
11	the 	O
12	inhibition 	O
13	of 	O
14	growth 	O
15	in 	O
16	a 	O
17	wide 	O
18	variety 	O
19	of 	O
20	normal 	O
21	and 	O
22	cancerous 	O
23	cells 	O
24	. 	O

1	We 	O
2	conclude 	O
3	that 	O
4	RPMS 	B
5	acts 	O
6	as 	O
7	a 	O
8	negative 	O
9	regulator 	O
10	of 	O
11	EBNA2 	B
12	and 	O
13	Notch 	B
14	activity 	O
15	through 	O
16	its 	O
17	interactions 	O
18	with 	O
19	the 	O
20	CBF1 	B
21	- 	I
22	associated 	I
23	corepressor 	I
24	complex 	I
25	. 	O

1	Isolated 	O
2	Systolic 	O
3	Hypertension 	O
4	: 	O
5	An 	O
6	Update 	O
7	. 	O

1	Transfection 	O
2	of 	O
3	EGFP 	B
4	- 	O
5	tagged 	O
6	DENTT 	B
7	NLS 	O
8	deletion 	O
9	constructs 	O
10	lacking 	O
11	the 	O
12	bipartite 	O
13	NLS 	B
14	- 	I
15	1 	I
16	were 	O
17	excluded 	O
18	from 	O
19	the 	O
20	nucleolus 	O
21	. 	O

1	VE 	O
2	- 	O
3	DEF 	O
4	animals 	O
5	had 	O
6	significantly 	O
7	higher 	O
8	( 	O
9	p 	O
10	< 	O
11	0 	O
12	. 	O
13	05 	O
14	) 	O
15	levels 	O
16	of 	O
17	myocardial 	O
18	lipid 	O
19	peroxidation 	O
20	and 	O
21	lower 	O
22	( 	O
23	p 	O
24	< 	O
25	0 	O
26	. 	O
27	05 	O
28	) 	O
29	protein 	O
30	thiols 	O
31	following 	O
32	I 	O
33	- 	O
34	R 	O
35	compared 	O
36	to 	O
37	the 	O
38	CON 	O
39	animals 	O
40	. 	O

1	The 	O
2	position 	O
3	of 	O
4	the 	O
5	analyst 	O
6	as 	O
7	expert 	O
8	: 	O
9	yesterday 	O
10	and 	O
11	today 	O
12	. 	O

1	Furthermore 	O
2	, 	O
3	we 	O
4	showed 	O
5	that 	O
6	ERSF 	B
7	including 	O
8	NF 	B
9	- 	I
10	Y 	I
11	and 	O
12	ATF6alpha 	B
13	and 	I
14	/ 	I
15	or 	I
16	beta 	I
17	and 	O
18	capable 	O
19	of 	O
20	binding 	O
21	to 	O
22	ERSE 	O
23	is 	O
24	indeed 	O
25	formed 	O
26	when 	O
27	the 	O
28	cellular 	O
29	UPR 	O
30	is 	O
31	activated 	O
32	. 	O

1	We 	O
2	performed 	O
3	the 	O
4	present 	O
5	study 	O
6	to 	O
7	clarify 	O
8	the 	O
9	relationship 	O
10	between 	O
11	the 	O
12	DOX 	O
13	binding 	O
14	ability 	O
15	(% 	O
16	DB 	O
17	) 	O
18	and 	O
19	the 	O
20	histologic 	O
21	response 	O
22	, 	O
23	rate 	O
24	of 	O
25	decrease 	O
26	in 	O
27	tumor 	O
28	volume 	O
29	of 	O
30	malignant 	O
31	soft 	O
32	tissue 	O
33	tumors 	O
34	after 	O
35	preoperative 	O
36	chemotherapy 	O
37	and 	O
38	prognosis 	O
39	. 	O

1	We 	O
2	have 	O
3	also 	O
4	isolated 	O
5	and 	O
6	analyzed 	O
7	the 	O
8	5 	O
9	' 	O
10	flanking 	O
11	region 	O
12	of 	O
13	the 	O
14	pea 	O
15	33RNP 	B
16	gene 	I
17	. 	O

1	We 	O
2	have 	O
3	previously 	O
4	shown 	O
5	that 	O
6	the 	O
7	adenoviral 	B
8	12S 	I
9	E1A 	I
10	protein 	I
11	modulates 	O
12	the 	O
13	phosphorylation 	O
14	status 	O
15	of 	O
16	p130 	B
17	and 	O
18	p107 	B
19	without 	O
20	apparent 	O
21	changes 	O
22	in 	O
23	the 	O
24	cell 	O
25	cycle 	O
26	dependent 	O
27	phosphorylation 	O
28	of 	O
29	the 	O
30	retinoblastoma 	B
31	protein 	I
32	. 	O

1	Baseline 	O
2	MBF 	O
3	in 	O
4	females 	O
5	was 	O
6	significantly 	O
7	( 	O
8	P 	O
9	< 	O
10	0 	O
11	. 	O
12	001 	O
13	) 	O
14	higher 	O
15	than 	O
16	in 	O
17	males 	O
18	. 	O

1	Only 	O
2	nine 	O
3	patients 	O
4	were 	O
5	offered 	O
6	surgery 	O
7	( 	O
8	six 	O
9	were 	O
10	resected 	O
11	and 	O
12	three 	O
13	were 	O
14	found 	O
15	inoperable 	O
16	). 	O

1	The 	O
2	deubiquitinating 	O
3	enzyme 	O
4	DUB 	B
5	- 	I
6	2 	I
7	is 	O
8	induced 	O
9	in 	O
10	response 	O
11	to 	O
12	IL 	B
13	- 	I
14	2 	I
15	but 	O
16	as 	O
17	yet 	O
18	its 	O
19	function 	O
20	has 	O
21	not 	O
22	been 	O
23	determined 	O
24	. 	O

1	A 	O
2	split 	O
3	motor 	O
4	domain 	O
5	in 	O
6	a 	O
7	cytoplasmic 	B
8	dynein 	I
9	. 	O

1	Immunological 	O
2	and 	O
3	biochemical 	O
4	characterization 	O
5	of 	O
6	streptococcal 	B
7	pyrogenic 	I
8	exotoxins 	I
9	I 	I
10	and 	I
11	J 	I
12	( 	O
13	SPE 	B
14	- 	I
15	I 	I
16	and 	O
17	SPE 	B
18	- 	I
19	J 	I
20	) 	O
21	from 	O
22	Streptococcus 	O
23	pyogenes 	O
24	. 	O

1	Five 	O
2	modalities 	O
3	of 	O
4	nonpharmacologic 	O
5	approaches 	O
6	are 	O
7	recommended 	O
8	at 	O
9	present 	O
10	for 	O
11	lifestyle 	O
12	modification 	O
13	and 	O
14	control 	O
15	of 	O
16	arterial 	O
17	blood 	O
18	pressure 	O
19	elevation 	O
20	: 	O
21	1 	O
22	) 	O
23	weight 	O
24	reduction 	O
25	to 	O
26	ideal 	O
27	body 	O
28	weight 	O
29	, 	O
30	since 	O
31	it 	O
32	reduces 	O
33	risk 	O
34	of 	O
35	hypertension 	O
36	as 	O
37	well 	O
38	as 	O
39	overall 	O
40	cardiovascular 	O
41	morbidity 	O
42	and 	O
43	mortality 	O
44	; 	O
45	2 	O
46	) 	O
47	dietary 	O
48	sodium 	O
49	restriction 	O
50	to 	O
51	less 	O
52	than 	O
53	2 	O
54	g 	O
55	a 	O
56	day 	O
57	, 	O
58	without 	O
59	assurance 	O
60	that 	O
61	it 	O
62	will 	O
63	normalize 	O
64	arterial 	O
65	pressure 	O
66	although 	O
67	it 	O
68	may 	O
69	help 	O
70	reduce 	O
71	dosage 	O
72	and 	O
73	numbers 	O
74	of 	O
75	prescribed 	O
76	antihypertensive 	O
77	drugs 	O
78	; 	O
79	3 	O
80	) 	O
81	moderation 	O
82	of 	O
83	alcohol 	O
84	consumption 	O
85	to 	O
86	less 	O
87	than 	O
88	1 	O
89	ounce 	O
90	a 	O
91	day 	O
92	; 	O
93	4 	O
94	) 	O
95	a 	O
96	regular 	O
97	isotonic 	O
98	exercise 	O
99	program 	O
100	; 	O
101	and 	O
102	5 	O
103	) 	O
104	cessation 	O
105	of 	O
106	tobacco 	O
107	consumption 	O
108	. 	O

1	Descriptions 	O
2	of 	O
3	this 	O
4	locus 	O
5	would 	O
6	allow 	O
7	comparison 	O
8	with 	O
9	functionally 	O
10	relevant 	O
11	molecular 	O
12	genetic 	O
13	features 	O
14	of 	O
15	other 	O
16	species 	O
17	' 	O
18	homologous 	O
19	loci 	O
20	including 	O
21	the 	O
22	single 	O
23	- 	O
24	copy 	O
25	equid 	O
26	LH 	B
27	/ 	O
28	CGbeta 	B
29	gene 	O
30	and 	O
31	the 	O
32	primate 	O
33	LHbeta 	B
34	- 	O
35	CGbeta 	B
36	gene 	O
37	cluster 	O
38	locus 	O
39	. 	O

1	METHODS 	O
2	: 	O
3	One 	O
4	hundred 	O
5	fourteen 	O
6	consecutive 	O
7	patients 	O
8	( 	O
9	mean 	O
10	age 	O
11	61 	O
12	years 	O
13	) 	O
14	with 	O
15	focal 	O
16	pancreatic 	O
17	masses 	O
18	, 	O
19	detected 	O
20	on 	O
21	CT 	O
22	, 	O
23	underwent 	O
24	EUS 	O
25	- 	O
26	FNA 	O
27	by 	O
28	using 	O
29	a 	O
30	linear 	O
31	- 	O
32	array 	O
33	echoendoscope 	O
34	and 	O
35	22 	O
36	- 	O
37	gauge 	O
38	needles 	O
39	. 	O

1	The 	O
2	effects 	O
3	of 	O
4	chlordiazepoxide 	O
5	( 	O
6	2 	O
7	. 	O
8	5 	O
9	- 	O
10	15 	O
11	. 	O
12	0mg 	O
13	/ 	O
14	kg 	O
15	), 	O
16	a 	O
17	full 	O
18	benzodiazepine 	B
19	receptor 	I
20	agonist 	O
21	, 	O
22	and 	O
23	bretazenil 	O
24	( 	O
25	5 	O
26	. 	O
27	0 	O
28	- 	O
29	30 	O
30	. 	O
31	0mg 	O
32	/ 	O
33	kg 	O
34	), 	O
35	a 	O
36	partial 	O
37	benzodiazepine 	B
38	receptor 	I
39	agonist 	O
40	, 	O
41	were 	O
42	examined 	O
43	in 	O
44	the 	O
45	murine 	O
46	elevated 	O
47	plus 	O
48	- 	O
49	maze 	O
50	paradigm 	O
51	. 	O

1	Acute 	O
2	effects 	O
3	of 	O
4	LI 	O
5	160 	O
6	( 	O
7	extract 	O
8	of 	O
9	Hypericum 	O
10	perforatum 	O
11	, 	O
12	St 	O
13	John 	O
14	' 	O
15	s 	O
16	wort 	O
17	) 	O
18	and 	O
19	two 	O
20	of 	O
21	its 	O
22	constituents 	O
23	on 	O
24	neuroendocrine 	O
25	responses 	O
26	in 	O
27	the 	O
28	rat 	O
29	. 	O

1	Guidelines 	O
2	for 	O
3	performing 	O
4	a 	O
5	routine 	O
6	spiral 	O
7	assay 	O
8	are 	O
9	presented 	O
10	, 	O
11	and 	O
12	alternative 	O
13	test 	O
14	methods 	O
15	intended 	O
16	to 	O
17	overcome 	O
18	a 	O
19	variety 	O
20	of 	O
21	technical 	O
22	difficulties 	O
23	( 	O
24	such 	O
25	as 	O
26	restricted 	O
27	sample 	O
28	availability 	O
29	, 	O
30	sample 	O
31	viscosity 	O
32	or 	O
33	volatility 	O
34	, 	O
35	etc 	O
36	.) 	O
37	are 	O
38	recommended 	O
39	. 	O

1	An 	O
2	additional 	O
3	9 	O
4	patients 	O
5	achieved 	O
6	normal 	O
7	levels 	O
8	with 	O
9	adjunctive 	O
10	drug 	O
11	therapy 	O
12	. 	O

1	Anti 	B
2	- 	I
3	nucleolin 	I
4	mAb 	I
5	was 	O
6	used 	O
7	to 	O
8	confirm 	O
9	the 	O
10	antigenic 	O
11	properties 	O
12	of 	O
13	this 	O
14	p95 	B
15	component 	I
16	. 	O

1	Eliminating 	O
2	any 	O
3	subset 	O
4	of 	O
5	ASCUS 	O
6	reduces 	O
7	the 	O
8	ASCUS 	O
9	/ 	O
10	SIL 	O
11	ratio 	O
12	but 	O
13	also 	O
14	significantly 	O
15	diminishes 	O
16	the 	O
17	sensitivity 	O
18	of 	O
19	the 	O
20	Papanicolaou 	O
21	test 	O
22	. 	O

1	Prrp 	B
2	can 	O
3	also 	O
4	associate 	O
5	with 	O
6	the 	O
7	EVH1 	B
8	domain 	I
9	of 	O
10	Mena 	B
11	, 	O
12	another 	O
13	microfilament 	O
14	- 	O
15	associated 	O
16	protein 	O
17	. 	O

1	Experience 	O
2	with 	O
3	xylene 	O
4	- 	O
5	free 	O
6	sections 	O
7	since 	O
8	1995 	O
9	at 	O
10	the 	O
11	Vrinnevi 	O
12	Hospital 	O
13	is 	O
14	favorable 	O
15	. 	O

1	Acquired 	O
2	antithrombin 	B
3	deficiency 	O
4	in 	O
5	sepsis 	O
6	. 	O

1	SIP1 	B
2	( 	O
3	Smad 	B
4	interacting 	I
5	protein 	I
6	1 	I
7	) 	O
8	and 	O
9	deltaEF1 	B
10	( 	O
11	delta 	B
12	- 	I
13	crystallin 	I
14	enhancer 	I
15	binding 	I
16	factor 	I
17	) 	O
18	are 	O
19	structurally 	O
20	similar 	O
21	transcriptional 	O
22	repressors 	O
23	. 	O

1	SERS 	O
2	spectra 	O
3	were 	O
4	obtained 	O
5	by 	O
6	vacuum 	O
7	evaporation 	O
8	and 	O
9	casting 	O
10	of 	O
11	p 	O
12	- 	O
13	NTP 	O
14	onto 	O
15	silver 	O
16	island 	O
17	films 	O
18	, 	O
19	and 	O
20	also 	O
21	from 	O
22	colloidal 	O
23	silver 	O
24	solutions 	O
25	. 	O

1	The 	O
2	moduli 	O
3	of 	O
4	elasticity 	O
5	of 	O
6	the 	O
7	gray 	O
8	and 	O
9	white 	O
10	matter 	O
11	were 	O
12	3 	O
13	. 	O
14	4 	O
15	+/- 	O
16	1 	O
17	. 	O
18	4 	O
19	kPa 	O
20	( 	O
21	mean 	O
22	+/- 	O
23	standard 	O
24	deviation 	O
25	) 	O
26	and 	O
27	3 	O
28	. 	O
29	4 	O
30	+/- 	O
31	0 	O
32	. 	O
33	9 	O
34	kPa 	O
35	in 	O
36	the 	O
37	axial 	O
38	section 	O
39	, 	O
40	3 	O
41	+/- 	O
42	0 	O
43	. 	O
44	3 	O
45	kPa 	O
46	and 	O
47	3 	O
48	. 	O
49	5 	O
50	+/- 	O
51	0 	O
52	. 	O
53	5 	O
54	kPa 	O
55	in 	O
56	the 	O
57	frontal 	O
58	section 	O
59	, 	O
60	and 	O
61	3 	O
62	. 	O
63	5 	O
64	+/- 	O
65	0 	O
66	. 	O
67	9 	O
68	kPa 	O
69	and 	O
70	2 	O
71	. 	O
72	8 	O
73	+/- 	O
74	0 	O
75	. 	O
76	4 	O
77	kPa 	O
78	in 	O
79	the 	O
80	sagittal 	O
81	section 	O
82	, 	O
83	respectively 	O
84	. 	O

1	[ 	O
2	Clinical 	O
3	and 	O
4	epidemiological 	O
5	characteristics 	O
6	of 	O
7	squamous 	O
8	cell 	O
9	carcinoma 	O
10	of 	O
11	the 	O
12	oral 	O
13	cavity 	O
14	in 	O
15	women 	O
16	] 	O
17	BACKGROUND 	O
18	: 	O
19	Squamous 	O
20	cell 	O
21	carcinoma 	O
22	( 	O
23	SCC 	O
24	) 	O
25	of 	O
26	the 	O
27	oral 	O
28	cavity 	O
29	occurs 	O
30	mainly 	O
31	in 	O
32	the 	O
33	male 	O
34	population 	O
35	. 	O

1	The 	O
2	core 	O
3	promoter 	O
4	of 	O
5	human 	B
6	thioredoxin 	I
7	reductase 	I
8	1 	I
9	: 	O
10	cloning 	O
11	, 	O
12	transcriptional 	O
13	activity 	O
14	, 	O
15	and 	O
16	Oct 	B
17	- 	I
18	1 	I
19	, 	O
20	Sp1 	B
21	, 	O
22	and 	O
23	Sp3 	B
24	binding 	O
25	reveal 	O
26	a 	O
27	housekeeping 	O
28	- 	O
29	type 	O
30	promoter 	O
31	for 	O
32	the 	O
33	AU 	O
34	- 	O
35	rich 	O
36	element 	O
37	- 	O
38	regulated 	O
39	gene 	O
40	. 	O

1	Phase 	O
2	II 	O
3	trial 	O
4	of 	O
5	the 	O
6	anti 	B
7	- 	I
8	G 	I
9	( 	I
10	D2 	I
11	) 	I
12	monoclonal 	I
13	antibody 	I
14	3F8 	I
15	and 	O
16	granulocyte 	B
17	- 	I
18	macrophage 	I
19	colony 	I
20	- 	I
21	stimulating 	I
22	factor 	I
23	for 	O
24	neuroblastoma 	O
25	. 	O

1	A 	O
2	log 	O
3	- 	O
4	linear 	O
5	dose 	O
6	- 	O
7	response 	O
8	was 	O
9	obtained 	O
10	for 	O
11	the 	O
12	average 	O
13	increase 	O
14	in 	O
15	FEV1 	O
16	up 	O
17	to 	O
18	6 	O
19	h 	O
20	( 	O
21	AUC0 	O
22	- 	O
23	6 	O
24	h 	O
25	) 	O
26	and 	O
27	peak 	O
28	FEV1 	O
29	across 	O
30	the 	O
31	dose 	O
32	range 	O
33	administered 	O
34	by 	O
35	Respimat 	O
36	. 	O

1	Plasma 	O
2	DHE 	O
3	concentration 	O
4	rose 	O
5	promptly 	O
6	above 	O
7	5 	O
8	ng 	O
9	/ 	O
10	ml 	O
11	after 	O
12	the 	O
13	application 	O
14	of 	O
15	the 	O
16	PSA 	O
17	tape 	O
18	onto 	O
19	the 	O
20	damaged 	O
21	skin 	O
22	in 	O
23	hairless 	O
24	rat 	O
25	. 	O

1	A 	O
2	complete 	O
3	drug 	O
4	history 	O
5	was 	O
6	compiled 	O
7	, 	O
8	specifying 	O
9	the 	O
10	amount 	O
11	and 	O
12	duration 	O
13	of 	O
14	VGB 	O
15	medication 	O
16	. 	O

1	Epithelial 	O
2	cytotoxicity 	O
3	of 	O
4	combined 	O
5	antibiotics 	O
6	was 	O
7	additive 	O
8	, 	O
9	with 	O
10	no 	O
11	evidence 	O
12	of 	O
13	competition 	O
14	or 	O
15	synergism 	O
16	. 	O

1	In 	O
2	Cd 	O
3	- 	O
4	spiked 	O
5	OECD 	O
6	soil 	O
7	, 	O
8	internal 	O
9	Cd 	O
10	levels 	O
11	were 	O
12	linearly 	O
13	related 	O
14	to 	O
15	external 	O
16	Cd 	O
17	concentrations 	O
18	, 	O
19	whereas 	O
20	the 	O
21	springtails 	O
22	maintained 	O
23	fixed 	O
24	internal 	O
25	levels 	O
26	of 	O
27	Cu 	O
28	and 	O
29	Zn 	O
30	regardless 	O
31	of 	O
32	spiked 	O
33	concentrations 	O
34	. 	O

1	Interestingly 	O
2	, 	O
3	the 	O
4	similarities 	O
5	with 	O
6	the 	O
7	endophilin 	B
8	proteins 	I
9	cover 	O
10	the 	O
11	entire 	O
12	sequence 	O
13	of 	O
14	the 	O
15	SH3GLB 	B
16	family 	I
17	, 	O
18	suggesting 	O
19	a 	O
20	common 	O
21	fold 	O
22	and 	O
23	presumably 	O
24	a 	O
25	common 	O
26	mode 	O
27	of 	O
28	action 	O
29	. 	O

1	Reovirus 	O
2	mRNAs 	O
3	are 	O
4	efficiently 	O
5	translated 	O
6	within 	O
7	host 	O
8	cells 	O
9	despite 	O
10	the 	O
11	absence 	O
12	of 	O
13	3 	O
14	' 	O
15	polyadenylated 	O
16	tails 	O
17	. 	O

1	Grippers 	O
2	with 	O
3	integrated 	O
4	piezoresistive 	O
5	force 	O
6	sensors 	O
7	and 	O
8	with 	O
9	attached 	O
10	strain 	O
11	gauges 	O
12	have 	O
13	been 	O
14	reported 	O
15	. 	O

1	Both 	O
2	Z 	B
3	and 	O
4	R 	B
5	expression 	O
6	resulted 	O
7	in 	O
8	PML 	O
9	dispersion 	O
10	in 	O
11	EBV 	O
12	- 	O
13	positive 	O
14	cells 	O
15	. 	O

1	The 	O
2	small 	O
3	copepod 	O
4	Pseudonychocamptus 	O
5	proximus 	O
6	progressively 	O
7	replaced 	O
8	the 	O
9	large 	O
10	Tisbe 	O
11	furcata 	O
12	in 	O
13	sand 	O
14	filters 	O
15	during 	O
16	the 	O
17	fall 	O
18	of 	O
19	1995 	O
20	and 	O
21	was 	O
22	responsible 	O
23	for 	O
24	the 	O
25	large 	O
26	increase 	O
27	in 	O
28	meiofaunal 	O
29	biomass 	O
30	observed 	O
31	after 	O
32	spring 	O
33	1996 	O
34	. 	O

1	Evidence 	O
2	- 	O
3	based 	O
4	care 	O
5	: 	O
6	a 	O
7	new 	O
8	formula 	O
9	for 	O
10	an 	O
11	old 	O
12	problem 	O
13	? 	O

1	Nrf2 	B
2	regulates 	O
3	expression 	O
4	of 	O
5	genes 	O
6	encoding 	O
7	enzymes 	O
8	with 	O
9	antioxidant 	O
10	( 	O
11	e 	O
12	. 	O
13	g 	O
14	. 	O
15	heme 	B
16	oxygenase 	I
17	- 	I
18	1 	I
19	( 	O
20	HO 	B
21	- 	I
22	1 	I
23	)) 	O
24	or 	O
25	xenobiotic 	O
26	detoxification 	O
27	( 	O
28	e 	O
29	. 	O
30	g 	O
31	. 	O

1	Workload 	O
2	, 	O
3	UAPs 	O
4	, 	O
5	and 	O
6	you 	O
7	. 	O

1	RESULTS 	O
2	: 	O
3	At 	O
4	latest 	O
5	examination 	O
6	, 	O
7	mean 	O
8	UPDRS 	O
9	II 	O
10	and 	O
11	III 	O
12	scores 	O
13	had 	O
14	improved 	O
15	by 	O
16	30 	O
17	% 	O
18	( 	O
19	on 	O
20	stimulation 	O
21	, 	O
22	off 	O
23	therapy 	O
24	) 	O
25	with 	O
26	mean 	O
27	50 	O
28	% 	O
29	reduction 	O
30	in 	O
31	daily 	O
32	off 	O
33	time 	O
34	. 	O

1	Perfusion 	O
2	technique 	O
3	for 	O
4	perfusion 	O
5	- 	O
6	assisted 	O
7	direct 	O
8	coronary 	O
9	artery 	O
10	bypass 	O
11	( 	O
12	PADCAB 	O
13	). 	O

1	Copyright 	O
2	2001 	O
3	Academic 	O
4	Press 	O
5	. 	O

1	The 	O
2	amount 	O
3	of 	O
4	drained 	O
5	effusion 	O
6	was 	O
7	measured 	O
8	, 	O
9	and 	O
10	fluid 	O
11	was 	O
12	sent 	O
13	for 	O
14	diagnostic 	O
15	assessment 	O
16	. 	O
